170 related articles for article (PubMed ID: 25252705)
21. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
[TBL] [Abstract][Full Text] [Related]
22. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.
Nelson PK; Mathers BM; Cowie B; Hagan H; Des Jarlais D; Horyniak D; Degenhardt L
Lancet; 2011 Aug; 378(9791):571-83. PubMed ID: 21802134
[TBL] [Abstract][Full Text] [Related]
23. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.
Zelenev A; Li J; Mazhnaya A; Basu S; Altice FL
Lancet Infect Dis; 2018 Feb; 18(2):215-224. PubMed ID: 29153265
[TBL] [Abstract][Full Text] [Related]
25. Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization's global health sector strategy core indicators and scaling up key interventions.
Duffell EF; Hedrich D; Mardh O; Mozalevskis A
Euro Surveill; 2017 Mar; 22(9):. PubMed ID: 28277217
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
[TBL] [Abstract][Full Text] [Related]
27. Progress toward prevention of transfusion-transmitted hepatitis B and hepatitis C infection--sub-Saharan Africa, 2000-2011.
Apata IW; Averhoff F; Pitman J; Bjork A; Yu J; Amin NA; Dhingra N; Kolwaite A; Marfin A;
MMWR Morb Mortal Wkly Rep; 2014 Jul; 63(29):613-9. PubMed ID: 25055184
[TBL] [Abstract][Full Text] [Related]
28. Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses.
Lazarus JV; Safreed-Harmon K; Stumo SR; Jauffret-Roustide M; Maticic M; Reic T; Schatz E; Tallada J; Harris M;
Int J Drug Policy; 2017 Sep; 47():47-50. PubMed ID: 28689856
[No Abstract] [Full Text] [Related]
29. Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments.
Wait S; Kell E; Hamid S; Muljono DH; Sollano J; Mohamed R; Shah S; Mamun-Al-Mahtab ; Abbas Z; Johnston J; Tanwandee T; Wallace J
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):248-255. PubMed ID: 28404097
[TBL] [Abstract][Full Text] [Related]
30. Role of direct and indirect social and spatial ties in the diffusion of HIV and HCV among people who inject drugs: a cross-sectional community-based network analysis in New Delhi, India.
Clipman SJ; Mehta SH; Srikrishnan AK; Zook KJ; Duggal P; Mohapatra S; Shanmugam S; Nandagopal P; Kumar MS; Ogburn E; Lucas GM; Latkin CA; Solomon SS
Elife; 2021 Aug; 10():. PubMed ID: 34342266
[TBL] [Abstract][Full Text] [Related]
31. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention.
Koester S; Glanz J; Barón A
AIDS Behav; 2005 Mar; 9(1):27-39. PubMed ID: 15812611
[TBL] [Abstract][Full Text] [Related]
32. State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs - United States, 2015-2016.
Campbell CA; Canary L; Smith N; Teshale E; Ryerson AB; Ward JW
MMWR Morb Mortal Wkly Rep; 2017 May; 66(18):465-469. PubMed ID: 28493854
[TBL] [Abstract][Full Text] [Related]
33. European survey of hepatitis B vaccination policies for healthcare workers: An updated overview.
De Schryver A; Lambaerts T; Lammertyn N; François G; Bulterys S; Godderis L
Vaccine; 2020 Mar; 38(11):2466-2472. PubMed ID: 32057571
[TBL] [Abstract][Full Text] [Related]
34. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
[TBL] [Abstract][Full Text] [Related]
35. Associations between national viral hepatitis policies/programmes and country-level socioeconomic factors: a sub-analysis of data from the 2013 WHO viral hepatitis policy report.
Lazarus JV; Sperle I; Safreed-Harmon K; Gore C; Cebolla B; Spina A
BMC Public Health; 2017 Jul; 18(1):16. PubMed ID: 28743246
[TBL] [Abstract][Full Text] [Related]
36. Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe.
Kautz A; Chavdarova L; Walker M
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S3. PubMed ID: 25253094
[No Abstract] [Full Text] [Related]
37. Hepatitis B: are at-risk individuals vaccinated if screened and found negative for HBV? Results of an online survey conducted in six EU countries.
Levi M; Ahmad A; Bechini A; Boccalini S; Nguyen QV; Veldhuijzen I; Richardus JH; Reintjes R; Bonanni P
Vaccine; 2014 Nov; 32(48):6415-20. PubMed ID: 25280438
[TBL] [Abstract][Full Text] [Related]
38. State of viral hepatitis care in 16 countries of Central and Eastern European Region.
Chkhartishvili N; Holban T; Simonović Babić J; Alexiev I; Matičič M; Kowalska J; Horban A;
Cent Eur J Public Health; 2019 Sep; 27(3):212-216. PubMed ID: 31580556
[TBL] [Abstract][Full Text] [Related]
39. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.
Altice FL; Azbel L; Stone J; Brooks-Pollock E; Smyrnov P; Dvoriak S; Taxman FS; El-Bassel N; Martin NK; Booth R; Stöver H; Dolan K; Vickerman P
Lancet; 2016 Sep; 388(10050):1228-48. PubMed ID: 27427455
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
